JP2021510702A5 - - Google Patents
Info
- Publication number
- JP2021510702A5 JP2021510702A5 JP2020538844A JP2020538844A JP2021510702A5 JP 2021510702 A5 JP2021510702 A5 JP 2021510702A5 JP 2020538844 A JP2020538844 A JP 2020538844A JP 2020538844 A JP2020538844 A JP 2020538844A JP 2021510702 A5 JP2021510702 A5 JP 2021510702A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- product according
- conjugate
- pharmaceutical product
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023186470A JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862617095P | 2018-01-12 | 2018-01-12 | |
| US62/617,095 | 2018-01-12 | ||
| US201862674483P | 2018-05-21 | 2018-05-21 | |
| US62/674,483 | 2018-05-21 | ||
| US201862700147P | 2018-07-18 | 2018-07-18 | |
| US62/700,147 | 2018-07-18 | ||
| US201862711423P | 2018-07-27 | 2018-07-27 | |
| US201862711421P | 2018-07-27 | 2018-07-27 | |
| US62/711,421 | 2018-07-27 | ||
| US62/711,423 | 2018-07-27 | ||
| US201862716796P | 2018-08-09 | 2018-08-09 | |
| US201862716788P | 2018-08-09 | 2018-08-09 | |
| US62/716,796 | 2018-08-09 | ||
| US62/716,788 | 2018-08-09 | ||
| PCT/US2019/013314 WO2019140271A2 (en) | 2018-01-12 | 2019-01-11 | Synergistic cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186470A Division JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021510702A JP2021510702A (ja) | 2021-04-30 |
| JP2021510702A5 true JP2021510702A5 (cg-RX-API-DMAC7.html) | 2022-01-19 |
Family
ID=67218383
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538844A Pending JP2021510702A (ja) | 2018-01-12 | 2019-01-11 | 相乗的がん治療 |
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11730836B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3737383A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2021510702A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20200110377A (cg-RX-API-DMAC7.html) |
| CN (2) | CN111587115A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019206623A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3087628A1 (cg-RX-API-DMAC7.html) |
| MX (3) | MX2020007442A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2020126774A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2019140271A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020219943A1 (en) | 2019-04-26 | 2020-10-29 | Prolynx Llc | Slow-release cytokine conjugates |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
| US12472261B2 (en) | 2019-08-28 | 2025-11-18 | Prolynx Llc | Conjugated inhibitors of DNA damage response |
| CN119213060A (zh) * | 2022-04-14 | 2024-12-27 | 国立研究开发法人量子科学技术研究开发机构 | 单一高分子颗粒、活性分子复合物、单一高分子颗粒的制造方法、肿瘤尺寸的计测方法、肿瘤内微细结构的计测方法、生物体组织的成像方法、药物递送体系、造影剂试剂盒 |
| US20260034120A1 (en) * | 2022-08-04 | 2026-02-05 | Prolynx Llc | Treating cancer with long-acting topoisomerase i inhibitor |
| WO2024030998A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Methods of treating cancer with long-acting topoisomerase i inhibitor |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2319854B1 (en) | 1997-01-08 | 2016-11-30 | Sigma-Aldrich Co. LLC | Bioconjugation Of Macromolecules |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| AU2003253890A1 (en) | 2002-07-12 | 2004-02-02 | Biomarin Pharmaceutical Inc. | The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| CA2502870C (en) | 2002-10-31 | 2011-07-26 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| CN1852740B (zh) | 2003-09-17 | 2011-05-11 | 耐科塔医药公司 | 多支链聚合物的药物前体 |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| MX2009002855A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales. |
| EP2307032A4 (en) * | 2008-05-22 | 2014-08-20 | Univ Ramot | NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS |
| CN102076331B (zh) | 2008-06-26 | 2013-12-18 | 普罗林科斯有限责任公司 | 具有可控的药物释放速率的前药和药物-大分子轭合物 |
| US20100098654A1 (en) | 2008-10-21 | 2010-04-22 | Fabio Pastorino | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| EP2366105A1 (en) | 2008-11-18 | 2011-09-21 | Baxter International Inc. | Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample |
| JP2012528240A (ja) | 2009-05-28 | 2012-11-12 | メルサナ セラピューティックス, インコーポレイテッド | 可変速度放出リンカーを含むポリアル−薬物コンジュゲート |
| CA2780645C (en) * | 2009-11-18 | 2018-01-16 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
| WO2011140393A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled release from macromolecular conjugates |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| WO2011140376A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from dendrimers |
| TW201215412A (en) | 2010-08-30 | 2012-04-16 | Sun Pharma Advanced Res Co Ltd | Stable pharmaceutical composition |
| CN108721284A (zh) * | 2010-11-16 | 2018-11-02 | 阵列生物制药公司 | 检测点激酶1抑制剂和wee1激酶抑制剂的组合 |
| WO2012088282A1 (en) | 2010-12-21 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| IN2014MN01819A (cg-RX-API-DMAC7.html) | 2012-03-05 | 2015-07-03 | Univ Ramot | |
| TWI486341B (zh) * | 2012-05-18 | 2015-06-01 | 高雄醫學大學 | 抑制atr與fancd2激活之組成物與方法 |
| WO2014194289A1 (en) * | 2013-05-31 | 2014-12-04 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
| CN106061483B (zh) * | 2013-10-04 | 2021-01-08 | 普洛林克斯有限责任公司 | Sn-38的缓释结合物 |
| WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015118338A1 (en) * | 2014-02-07 | 2015-08-13 | Mission Therapeutics Limited | Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways |
| US20150343100A1 (en) * | 2014-05-28 | 2015-12-03 | Memorial Sloan Kettering Cancer Center | Bimodal fluorophore-labeled liposomes and associated methods and systems |
| EP3180031A1 (en) * | 2014-08-13 | 2017-06-21 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| WO2016028636A1 (en) | 2014-08-16 | 2016-02-25 | Memorial Sloan Kettering Cancer Center | Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods |
| JP6378584B2 (ja) | 2014-08-29 | 2018-08-22 | キヤノン株式会社 | 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム |
| US10196412B2 (en) * | 2014-12-24 | 2019-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Probe for imaging PARP-1 activity |
| PL3277681T3 (pl) | 2015-04-02 | 2019-10-31 | Merck Patent Gmbh | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm |
| HK1250646A1 (zh) * | 2015-04-07 | 2019-01-11 | Memorial Sloan Kettering Cancer Center | 纳米粒子免疫偶联物 |
| US10973925B2 (en) * | 2015-04-28 | 2021-04-13 | University Of Central Florida Research Foundation Inc. | Methods and compositions for theranostic nanoparticles |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| US10821195B2 (en) | 2015-09-10 | 2020-11-03 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted PET imaging and methods of their use |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| US11154538B2 (en) | 2016-02-29 | 2021-10-26 | Synta Pharmaceuticals Corporation | Combination therapy for treatment of ovarian cancer |
| WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| RU2725292C2 (ru) | 2016-04-27 | 2020-06-30 | Иммьюномедикс, Инк. | Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей |
| AU2017258415B2 (en) * | 2016-04-29 | 2023-03-30 | Cornell University | Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors |
| CN106084005B (zh) * | 2016-06-15 | 2020-02-14 | 广州军区广州总医院 | 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用 |
| CN107050471A (zh) * | 2016-12-27 | 2017-08-18 | 中国药科大学 | 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用 |
-
2019
- 2019-01-11 JP JP2020538844A patent/JP2021510702A/ja active Pending
- 2019-01-11 KR KR1020207023337A patent/KR20200110377A/ko not_active Ceased
- 2019-01-11 KR KR1020207023338A patent/KR20200109345A/ko not_active Ceased
- 2019-01-11 MX MX2020007442A patent/MX2020007442A/es unknown
- 2019-01-11 AU AU2019206623A patent/AU2019206623A1/en not_active Abandoned
- 2019-01-11 CA CA3087628A patent/CA3087628A1/en active Pending
- 2019-01-11 CA CA3087967A patent/CA3087967A1/en active Pending
- 2019-01-11 JP JP2020538819A patent/JP2021510701A/ja active Pending
- 2019-01-11 WO PCT/US2019/013314 patent/WO2019140271A2/en not_active Ceased
- 2019-01-11 EP EP19738883.8A patent/EP3737383A4/en not_active Withdrawn
- 2019-01-11 WO PCT/US2019/013306 patent/WO2019140266A1/en not_active Ceased
- 2019-01-11 EP EP19738881.2A patent/EP3737416A4/en not_active Withdrawn
- 2019-01-11 RU RU2020126774A patent/RU2020126774A/ru unknown
- 2019-01-11 AU AU2019208024A patent/AU2019208024A1/en not_active Abandoned
- 2019-01-11 CN CN201980008227.1A patent/CN111587115A/zh active Pending
- 2019-01-11 US US16/961,640 patent/US11730836B2/en active Active
- 2019-01-11 CN CN201980008252.XA patent/CN111587126A/zh active Pending
- 2019-01-11 US US16/961,633 patent/US20200360545A1/en not_active Abandoned
- 2019-01-11 MX MX2020007306A patent/MX2020007306A/es unknown
-
2020
- 2020-07-13 MX MX2023005786A patent/MX2023005786A/es unknown
-
2023
- 2023-03-07 US US18/118,650 patent/US20230321286A1/en not_active Abandoned
- 2023-07-11 US US18/220,742 patent/US20240082436A1/en not_active Abandoned
- 2023-10-31 JP JP2023186470A patent/JP7703001B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bonelli et al. | Precision medicine in gastric cancer | |
| Chen et al. | Improving radiotherapy in cancer treatment: Promises and challenges | |
| Aghajanian et al. | Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer | |
| Begg et al. | Strategies to improve radiotherapy with targeted drugs | |
| Drost et al. | Opportunities and hurdles in the treatment of BRCA1-related breast cancer | |
| Mauclet et al. | Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab | |
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| JP2017519006A5 (cg-RX-API-DMAC7.html) | ||
| WO2010063011A3 (en) | Methods for the treatment of infections and tumors | |
| WO2012061683A3 (en) | Methods for treating cancer | |
| JP2012528890A5 (cg-RX-API-DMAC7.html) | ||
| JP2019508429A5 (cg-RX-API-DMAC7.html) | ||
| Arrighetti et al. | Drug combinations with HDAC inhibitors in antitumor therapy | |
| US20220288404A1 (en) | Methods for applying tumor treating fields in combination with cancer treating therapeutics | |
| Rotolo et al. | Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach | |
| Sandomenico et al. | Bevacizumab in non small cell lung cancer: development, current status and issues | |
| AU2020296087A1 (en) | Patient selection for enhancement of anti-tumor immunity in cancer patients | |
| Cutsem et al. | The role of chemotherapy in the current treatment of gastric cancer | |
| Dong et al. | Advances in evidence‐based medicine for immunotherapy of non‐small cell lung cancer | |
| Crinò et al. | Present and future treatment of advanced non–small cell lung cancer | |
| AU2017324860A1 (en) | PD-1 specific aptamers | |
| Folprecht | Liver Metastases in Colorectal Cancer. | |
| Voorhees et al. | Final results of a phase 1 study of vorinostat, pegylated liposomal doxorubicin, and bortezomib in relapsed or refractory multiple myeloma | |
| DiPasco et al. | The thrombophilic state in cancer part II: cancer outcomes, occult malignancy, and cancer suppression | |
| Karavasilis | Small cell lung cancer: current and future strategies |